EGFR and non-small cell lung carcinoma: The drug testing in our research is done using the EGFR inhibitor gefitinib, which is a first-line therapy against the EGFR-mutated non-small cell lung cancer, followed by detecting the expression of epidermal growth factor receptor (EGFR) under normoxic condition and hypoxia-inducible factor 1-alpha (HIF-1α) under hypoxic condition.